Drug Trial Radar · NCT02946463
ALXN1210 (Ravulizumab) Versus Eculizumab in Complement Inhibitor Treatment-Naïve Adult Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)
Last checked: Nov 20, 2026Latest source record: May 14, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
272
Actual
Start
Dec 12, 2016
Primary completion
Feb 28, 2023
Study completion Feb 28, 2023
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 27, 2016
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose of this study was to assess the noninferiority of ravulizumab compared to eculizumab in adult participants with PNH who had never been treated with a complement inhibitor (treatment-naïve).
Conditions
- Paroxysmal Nocturnal Hemoglobinuria (PNH)
Interventions
RavulizumabBiological
All treatments were given as intravenous (IV) infusions. For participants weighing ≥40 to \<60 kilogram (kg): 2400 mg was given as a single loading dose, followed by 3000 mg as maintenance dose. For participants weighing ≥60 to \<100 kg: 2700 mg was given as a loading dose, followed by 3300 mg as maintenance dose. For participants weighing ≥100 kg: 3000 mg was given as a loading dose, followed by 3600 mg as maintenance dose.
EculizumabBiological
All treatments were given as IV infusions. Participants were administered induction doses of 600 mg followed by maintenance doses of 900 mg.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion Of Participants With Normalization Of Lactate Dehydrogenase (LDH) LevelsTime frame: Day 29 through Day 183
- Percentage Of Participants Who Achieved Transfusion Avoidance (TA)Time frame: Baseline through Day 183
Locations
120 sites in 26 countries. Site status is shown where the registry gives one.
Research Site
Los Angeles, California
Research Site
Whittier, California
Research Site
Fort Worth, Texas
Research Site
Buenos Aires, Argentina
Research Site
Buenos Aires, Argentina
Research Site
Córdoba, Argentina
Research Site
Perth, Australia
Research Site
Linz, Austria
Research Site
Vienna, Austria
Research Site
Brussels, Belgium
Research Site
Hasselt, Belgium
Research Site
Leuven, Belgium
Research Site
Rio de Janeiro, Brazil
Research Site
Salvador, Brazil
Research Site
São Paulo, Brazil
Research Site
São Paulo, Brazil
Research Site
Edmonton, Alberta, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Pilsen, Czechia
Research Site
Prague, Czechia
Research Site
Tallinn, Estonia
Research Site
Limoges, France
Research Site
Montpellier, France
Research Site
Paris, France
Research Site
Pierre-Bénite, France
Research Site
Poitiers, France
Research Site
Rennes, France
Research Site
Aachen, Germany
Research Site
Essen, Germany
Research Site
Ulm, Germany
Research Site
Ascoli Piceno, Italy
Research Site
Florence, Italy
Research Site
Milan, Italy
Research Site
Naples, Italy
Research Site
Vicenza, Italy
Research Site
Bunkyō City, Japan
Research Site
Bunkyō City, Japan
Research Site
Fukuoka, Japan
Research Site
Fukushima, Japan
Research Site
Hamamatsu, Japan
Showing 40 of 120 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.